0 results for 'Sanofi US Services Inc'
Treatment of Antibody Claims In the U.S. After 'Amgen v. Sanofi'
The future of antibody claiming in the United States is uncertain following the U.S. Supreme Court's ruling in 'Amgen Inc. v. Sanofi,' a highly anticipated decision concerning enablement and whether the traditional way to claim antibodies — claiming antibodies by their function — will survive as a valid claiming strategy.Judge Rejects Class Action Claim Filed Against Novo Nordisk, Eli Lilly and Sanofi-Aventis
"Plaintiffs have not sufficiently shown they failed to receive the benefit of the bargain as they have not alleged that they had 'a reasonable belief about the product induced by a misrepresentation'—and in fact they have asserted the opposite, that their ascertainable loss theory is not based on misrepresentation—or that they were misled into buying insulin that was worth less than was promised," Judge Brian R. Martinotti said.Arnold & Porter Sees Revenue and Profits Jump, With PEP Rising 15% to $1.6M
The environment for counsel on government-facing issues was "quite strong" last year, driving demand across the firm's litigation, transaction and regulatory practices, said chairman Richard Alexander.Deal Watch: Debt Offerings Surge as Markets Begin to Turn
"It is booming right now," said Wachtell partner John Sobolewski of the liability management market.Pharmaceutical Legal and Regulatory Trends To Watch in 2024
This article highlights several notable legal and regulatory developments in 2023 and discusses developments that will continue to shape the pharmaceutical industry in 2024.View more book results for the query "Sanofi US Services Inc"
The Top Five Patent Decisions of 2023
From life sciences to industrial designs to trade shows, these decisions spanned a wide variety of patent law issues and signal that Constitutional patent rights are still exploring new legal questions and breaking new ground almost 250 years after our nation's founding, says Armond Wilson's Monica Arnold and Michelle Armond.'10's of Billions at Stake': Insulin Case Gets OK with Miami Attorney in Lead
"This is a case that goes back 20 years, so the damages are substantial," said the Miami attorney representing the MDLJuror Attitudes Toward Pharmaceutical Companies
In February 2023, the DOAR Research Center sought to shed light on changing attitudes toward the pharmaceutical industry by conducting a survey, which questioned respondents on their opinions of the pharmaceutical industry and their COVID-19 experiences. This article highlights the results of the survey.Senior Canadian Pharma GC Joins Fasken in Montreal
Robert Quesnel was head of legal affairs at Paris-based Sanofi for 15 before joining the national law firm.Download Now
Download Now
Download Now
Download Now